NCT06966687

Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)

• Status: Enrolling By Invitation
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Nanjing Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with thymosin alpha 1 in addition to antiinflammatory treatment may be beneficial. This study was designed to test the hypothesis that the administration of Ulinastatin and Thymosin α1 during the acute phase of AAS will result in a reduced incidence of SIRS and MODS.

Conditions

• Aortic Dissection
• Aortic Dissection Aneurysm

Interventions

Type	Name	Description
DRUG	Ulinastatin and Thymosin α1	Ulinastatin (100000U TID for 5 days) and Thymosin alpha 1 (1.6 mg q12h for 5 days) immediately after surgery
DRUG	Ulinastatin only	Ulinastatin (100000U TID for 5 days) immediately after surgery

Timeline

• Start date: 2025-04-01
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2025-05-13
• Last updated: 2026-01-14

Locations

4 sites across 1 country: China